Physician profile
Huma Khan
NPI 1750849253
$778.87
in general payments reported to CMS, 2019-2025
11 companies · $371 in 2025
The $371 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $22.39 · 2024: $386 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $779.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $778.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $141.83 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $111.69 | 2024-2025 | Camzyos |
| Novo Nordisk INC | $107.48 | 2024-2025 | Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $98.52 | 2024 | |
| Astellas Pharma US INC | $97.24 | 2025 | Veozah |
| Baxter Healthcare | $51.77 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Amgen INC. | $47.44 | 2024-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $45.51 | 2024 | Wainua, Farxiga |
| Medtronic, INC. | $28.86 | 2024 | Linq II |
| Pfizer INC. | $26.14 | 2024 | |
| Ucb, INC. | $22.39 | 2023 | Briviact |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Huma Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.